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Abstract: Hypertension remains a significant health burden in the United States, with almost one 
in three adults affected, and is an independent risk factor for cardiovascular and renal disease. The 
goal of antihypertensive treatment is to reduce cardiovascular and renal morbidity and mortality 
by reducing blood pressure (BP). Guidelines recommend a target BP of ,140/90 mmHg, with 
a more stringent goal of ,130/80 mmHg for patients with diabetes and chronic renal disease. 
However, BP goal attainment rates remain low and most patients require therapy with two or 
more antihypertensive agents. Combination antihypertensive therapy usually employs agents 
from different classes, thus benefitting from complementary mechanisms of action to achieve 
greater BP control with fewer side effects. Patient adherence to therapy is enhanced by formu-
lating treatments as fixed-dose (single-pill) combinations. One example is the combination of 
amlodipine, a dihydropyridine calcium channel blocker (CCB), with olmesartan medoxomil, an 
angiotensin receptor blocker (ARB). Here, the rationale for the use of CCB/ARB combination 
therapy is discussed, as well as the pharmacology and tolerability of the amlodipine/olmesartan 
medoxomil combination and its efficacy in terms of achieving BP goal in patients with hyperten-
sion. Advantages of its use from the patient’s perspective are also discussed.
Keywords: amlodipine, angiotensin receptor blockers, calcium channel blockers, fixed-dose 
combination therapy, hypertension, olmesartan medoxomil
Introduction
Hypertension affects nearly 1 in 3 adults in the United States,1−3 and is an   important 
modifiable risk factor for coronary artery disease, heart failure, renal   failure, and 
stroke.4,5 An analysis of global data suggests that the overall prevalence of   hypertension 
is similar in men and women and increases with age.6 According to a recent estimate, 
hypertension was responsible for around 7.6 million premature deaths per year, con-
tributing 6.0% to the total global disease burden.7
Hypertension control correlates with a significant reduction in cardiovascular 
(CV) events.2 Indeed, over the last 50 years, reductions observed in CV   event-related 
  morbidity and mortality have been attributed to the increased availability and use of 
antihypertensive treatments.2 In particular, blood pressure (BP) reductions in patients 
with   diabetes   mellitus are linked with reductions in disease events.8 However, the United 
States National Health and Nutrition Examination Survey (NHANES)   findings for 
2003 to 2004 showed that adequate BP control was achieved in only 37% of patients 
with   hypertension and in only 57% of those who received antihypertensive   therapy.1 
  Furthermore, because hypertension can be asymptomatic, many patients go   undiagnosed 
and thus it remains a major public health   challenge in the United States.1Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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American guidelines for the management of hypertension 
recommend that all individuals should achieve a BP target of 
at least ,140/90 mmHg, with a target of ,130/80 mmHg 
for patients with diabetes or chronic renal disease.4,9 Recently 
revised guidelines from the European Society of   Hypertension 
(ESH) recommend lowering BP to values within the range of 
130–139/80–85 mmHg in all patients with hypertension.10 How-
ever, despite agreement over the benefits of   hypertension control, 
there is no consensus as to the   optimal choice of antihypertensive 
agents.4 Additionally, recent guidelines recommend different 
antihypertensive   protocols depending on the underlying mor-
bidities and patient characteristics.4 For example, in patients with 
stable angina, a beta (β)-blocker and an angiotensin-converting 
enzyme (ACE) inhibitor or an angiotensin receptor blocker 
(ARB) are recommended, whereas in patients with severe left 
ventricular (LV)   dysfunction, the addition of an aldosterone 
antagonist and a thiazide or loop diuretic are recommended. In 
Black patients with severe LV dysfunction, the combination of 
hydralazine/isosorbide dinitrate is recommended as an adjunct 
to diuretic, ACE inhibitor or ARB, and β-blocker regimens.4 
In all cases of hypertension, lifestyle   modifications including 
weight loss, diet changes, exercise, smoking cessation, and 
alcohol moderation are recommended.4,11
Concept of combination therapy  
to attain BP goals
Hypertension treatment guidelines emphasize the   importance 
of starting treatment with combination therapy, especially 
in patients whose BP exceeds the goal by more than 
20/10 mmHg.9 Guidelines recommend combining different 
classes of antihypertensive agents that have complementary 
mechanisms of action, an antihypertensive effect that is 
greater than that of either component alone, and a favorable 
tolerability profile.8 Furthermore, patient adherence appears 
to be greater with single-pill combination treatment because 
of greater efficacy and a reduced pill burden.10,12
Recently  published  results  from  a  randomized, 
  double-blind study showed effective BP lowering with combi-
nation therapy.13 Each of the three dual-therapy   combinations 
produced significant (P , 0.0001 vs   baseline) reductions 
from baseline in both mean seated systolic BP (SeSBP) and 
diastolic BP (SeDBP) in patients with   moderate or severe 
hypertension (N = 2,271). The therapies were all possible dual 
  combinations of a dihydropyridine calcium channel blocker 
(DHP-CCB; amlodipine), a thiazide diuretic (hydrochloro-
thiazide [HCTZ]), and an ARB (valsartan). The DHP-CCB/
ARB combination produced numerically greater BP reduc-
tions than the other   combinations.13 A triple   combination of 
these agents enabled even greater reductions than the dual 
therapies and has been approved by the United States Food 
and Drug Administration (FDA).
Current antihypertensive  
drug options
Several effective classes of antihypertensive drugs are 
  currently available, including ACE inhibitors, ARBs, a direct 
renin inhibitor, β-blockers, CCBs, and thiazide-type   diuretics. 
Two-drug combinations found to be effective and well toler-
ated include: ACE inhibitor/thiazide diuretic, ARB/thiazide 
diuretic, DHP-CCB/ACE inhibitor, DHP-CCB/ARB, DHP-
CCB/thiazide diuretic, DHP-CCB/β-blocker, direct renin 
inhibitor/HCTZ,8 and a very recently FDA-approved direct 
renin inhibitor/ARB combination.14 Figure 1 shows possible 
combinations of some of these classes of agents; preferred 
combinations recommended by treatment guidelines are 
indicated with a thick line.
The rationale for fixed-dose  
(single-pill) combinations  
of DHP-CCBs and ARBs
Single-pill DHP-CCB/ARB combinations are emerging 
as convenient and rational options for antihypertensive 
treatment.15 As previously demonstrated, combination 
  antihypertensive therapy provides greater BP-lowering 
effects than single-agent therapy, and the added benefit 
of a DHP-CCB/ARB combination is a reduction in the 
  incidence of adverse events.15 For example, when an ARB 
and DHP-CCB are administered together, the   complementary 
  BP-reducing mechanism of action of an ARB appears to 
offset DHP-CCB–induced edema.15
Furthermore, ARBs can be used at increasingly higher doses 
without compromising tolerability,16 have   organ-protective 
effects,17 and are associated with a lower risk of cough and 
angioedema compared with ACE inhibitors.18 In addition to 
a mechanism of action complementary to ARBs, CCBs also 
provide CV benefits.19 An amlodipine-based treatment regi-
men prevented more CV events in the BP-lowering arm of the 
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) com-
pared with atenolol–based therapy.20 In patients with coronary 
artery disease and diastolic BP (DBP) ,100 mmHg, treatment 
with amlodipine reduced the incidence of CV events compared 
with placebo in the CAMELOT (Comparison of Amlodipine 
vs Enalapril to Limit Occurrences of Thrombosis) study.21 
Administration of CCBs has been shown to be associated with 
stroke prevention relative to other antihypertensive agents, as 
well as a reduction in all-cause mortality.19Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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In the ACCOMPLISH (Avoiding Cardiovascular Events 
Through Combination Therapy in Patients Living with 
Systolic Hypertension) trial, a DHP-CCB/ACE inhibitor 
(benazepril) combination provided a greater reduction in 
CV events in patients with hypertension at high risk for 
such events than was provided with a diuretic (HCTZ)/
ACE   inhibitor combination.22 BP control (,140/90 mmHg) 
was achieved by 74.5% and 72.4% of patients in the DHP-
CCB/ACE inhibitor and diuretic/ACE inhibitor groups, 
  respectively. It is possible to speculate that by extrapolating 
these data to DHP-CCB/ARB combinations similar benefits 
may be observed because both ACE inhibitors and ARBs act 
on the renin-angiotensin-aldosterone system (RAAS).
Results from the large ONTARGET (Ongoing   Telmisartan 
Alone and in Combination with Ramipril Global Endpoint 
Trial) study in patients with vascular disease or high-risk 
diabetes showed that treatment with an ARB (telmisartan) was 
associated with a reduction in death from CV causes, myo-
cardial infarction or stroke, or hospitalization for heart failure 
(primary endpoint) that was equivalent to the risk reduction 
observed with an ACE inhibitor.18 Of note, the rates of angioe-
dema (P , 0.01) and cough (P , 0.001) were significantly 
lower in the ARB group than in the ACE inhibitor group.18 
In the LIFE (Losartan Intervention For Endpoint reduction in 
hypertension) study, losartan prevented more death and CV 
morbidity than atenolol and was better tolerated.23
In the United States, a fixed-dose combination of amlodipine 
and olmesartan medoxomil (AZOR®; Daiichi Sankyo, Inc.; 
Parsippany, NJ; 5/20, 5/40, 10/20, and 10/40 mg) is indicated 
for first-line treatment in patients unlikely to reach their BP goal 
with monotherapy.24 This article will review the mechanism of 
action, pharmacology, and pharmacokinetics of amlodipine/
olmesartan medoxomil, and evaluate the efficacy of this com-
bination for achieving BP goals in patients with hypertension. 
The tolerability of the combination will also be discussed, along 
with advantages of its use from the patient’s perspective.
Amlodipine/olmesartan  
medoxomil: pharmacokinetics  
and mechanism of action
Amlodipine pharmacokinetics
Following oral administration of therapeutic dosages, amlo-
dipine is slowly absorbed from the gastrointestinal (GI) 
tract, and the time to peak plasma concentrations is 10 to 
14 hours.25 Steady-state concentrations are reached after 7 
to 8 days. Amlodipine does not undergo significant first-pass 
metabolism, but is slowly metabolized to inactive metabolites 
Thiazide diuretics
Angiotensin receptor
antagonists
Calcium antagonists
ACE
inhibitors
β-blockers
α-blockers
Figure 1 Possible combinations between some classes of antihypertensive agents. Framed agents have shown clinical benefit in interventional trials. Reproduced with 
permission from Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial 
hypertension of the european Society of Hypertension (eSH) and of the european Society of Cardiology (eSC). J Hypertens. 2007;25(6):1105–1187. Copyright © 2007 
Lippincott, williams & wilkins.
Abbreviation: ACe, angiotensin-converting enzyme.Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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in the liver.26 Primarily excreted in the urine, amlodipine has 
an elimination half-life of 35 to 45 hours.25
Olmesartan medoxomil  
pharmacokinetics
Olmesartan medoxomil is a prodrug that undergoes ester hydro-
lysis in the GI tract to form its active metabolite (olmesartan), 
which, once absorbed, does not undergo   further metabolism and 
is excreted in the urine.27 After rapid absorption from the GI 
tract, peak plasma concentrations are achieved in 1 to 2 hours, 
followed by an elimination half-life of 13 hours.24 Steady-state 
concentrations are reached within 3 to 5 days, and accumulation 
in the plasma does not occur with once-daily dosing.24
Pharmacokinetics of amlodipine and 
olmesartan medoxomil administered  
as a combination
No significant pharmacokinetic drug–drug interactions occur 
when olmesartan medoxomil and amlodipine are co-  administered 
in separate dosage forms.28,29 When orally administered as a 
fixed-dose combination, amlodipine/  olmesartan medoxomil is 
bioequivalent to single-entity dosage forms of both drugs.28
Bioequivalence was demonstrated during single- and 
  multi-dose phase I trials in healthy volunteers who received 
concomitant amlodipine and olmesartan   medoxomil in separate 
dose forms and together in a   fixed-dose   amlodipine/  olmesartan 
medoxomil 10/40 mg tablet   formulation (Figure 2).28 For exam-
ple, following a single dose of the combination tablet, peak 
plasma concentrations of amlodipine and olmesartan were 7.6 
and 833.3 ng/mL, and values for the area under the plasma 
  concentration-time curve were 424.8 and 5,374.2 ng⋅h/mL, 
  respectively.28   Corresponding values following administration 
of   amlodipine 10 mg and olmesartan medoxomil 40 mg as two 
separate   dosage forms were 7.4 and 810.3 ng/mL and 410.9 
and 5,418.6 ng⋅h/mL, respectively.28
Other pharmacokinetic parameters remain similar when 
amlodipine and olmesartan medoxomil are administered in 
either a fixed-dose combination or as individual   components. 
For instance, peak plasma concentrations in the fixed-dose 
combination were achieved in about 8 hours for amlodipine 
and 2 hours for olmesartan, and terminal elimination half-
lives in the fixed-dose combination were about 40 to 55 hours 
for amlodipine and 11 to 16 hours for olmesartan.28
Mechanism of action
ARBs
Angiotensin receptor blockers act by selectively binding to 
the AT1 receptor, blocking the effects of angiotensin II, and 
therefore suppressing vasoconstriction and other adverse 
CV effects of angiotensin II.30−32 Angiotensin II is the 
predominant effector peptide of the RAAS, which plays 
a key role in fluid and electrolyte balance and ultimately, 
BP regulation.30
Compared with most other ARBs, olmesartan medoxomil 
exhibits a high degree of selectivity for the AT1 receptor, to 
which it binds with high affinity. In vitro findings showed that 
olmesartan was second only to telmisartan in binding affinity 
for the AT1 receptor; the other comparators were   candesartan, 
valsartan, and losartan.33 Like other ARBs, olmesartan 
medoxomil has a low affinity for the AT2   receptor, which 
is also activated by angiotensin II, but is believed to have 
a vasodilatory effect and a protective role in BP   regulation 
and sodium excretion (Figure 3).34
CCBs
Calcium channel blockers decrease the entry of calcium ions 
into cells by blocking L-type calcium channels, leading to 
relaxation of arterial smooth muscle, peripheral   vasodilation, 
and lowered BP.35 Peripheral vasodilation is achieved through 
greater effects on calcium channels in arteries and arterioles 
than on cardiac muscle cells; CCBs do not affect serum 
calcium levels (Figure 3).
Efficacy of amlodipine and 
olmesartan medoxomil 
combination therapy
COACH study
The efficacy of an amlodipine + olmesartan medoxomil 
free combination was assessed in patients (N = 1,940) with 
mild-to-severe hypertension in the COACH (  Combination 
of   Olmesartan Medoxomil and Amlodipine Besylate in 
  Controlling High Blood Pressure) study, which was a 
  randomized, double-blind, placebo-controlled study   conducted 
over eight weeks.36 Patients were aged $18 years with an 
SeDBP of 95 to 120 mmHg. The 12 treatment groups were: 
amlodipine 5 or 10 mg monotherapy, olmesartan medoxomil 
10, 20, or 40 mg monotherapy, each possible amlodipine + 
olmesartan medoxomil combination, and placebo.
The primary endpoint was the change from baseline in 
mean SeDBP at the end of the 8-week   double-blind treatment 
period using the last observation carried   forward (LOCF) 
method. Secondary variables included the   proportions of 
patients achieving prespecified JNC 7 (Seventh Report of the 
Joint National Committee on   Prevention,   Detection, Evalua-
tion, and Treatment of High Blood Pressure)9   recommended BP 
goals. The safety analysis also included an active assessment Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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of edema, with specific   ratings for the incidence and severity 
of peripheral edema at scheduled visits. Edema was recorded 
as an adverse event when its severity increased following 
randomization.
The mean seated BP (SeBP) of the 1,940 patients who 
were randomized was 164/102 mmHg, and 79.3% had Stage 
2 hypertension. The majority of patients were white (71.4%), 
19.8% were aged $65 years, and 54.3% were male. In the 
study cohort, there were 13.5% of patients with diabetes and 
64.6% with a body mass index (BMI) $ 30 kg/m2.
At 8 weeks, significant reductions from baseline in SeDBP 
(primary endpoint) were observed in all active   treatment groups 
and in those receiving placebo (P , 0.001 for all groups). 
Reductions from baseline in SeSBP were also significant in all 
active treatment groups (P , 0.001) and in placebo recipients 
(P , 0.05). Of note, SeDBP   reductions with combination 
treatment were significantly greater than those observed with 
equivalent doses of   monotherapy with either amlodipine or olm-
esartan medoxomil (Figure 4). Mean changes from baseline in 
mean SeDBP with   amlodipine + olmesartan medoxomil ranged 
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Figure 2 Mean plasma concentration profiles of amlodipine (upper panel) and olmesartan (lower panel) after administration of single-pill amlodipine/olmesartan medoxomil 
10/40 mg combination therapy and concomitant administration of the two drugs and single tablets. Reproduced with permission from Rohatagi S, Lee J, Shenouda M, 
et al. Pharmacokinetics of   amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose 
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from −14.0 to −19.0 mmHg with 5 + 20 mg and 10 + 40 mg, 
respectively, whereas changes with monotherapy dosages of 
amlodipine were −9.4 mmHg (5 mg) and −12.7 mmHg (10 mg), 
and with   olmesartan medoxomil were −8.3 mmHg (10 mg), 
−9.2 mmHg (20 mg), and −10.2 mmHg (40 mg) (P , 0.001 
for all comparisons vs combination treatment).
Similarly, dose-dependent reductions in SeSBP were 
greater with combination amlodipine + olmesartan   medoxomil 
ARB MOA CCB MOA
Complementary
actions
ADDITIVE BP LOWERING
Angiotensin II
L-type Ca++ Channel
ARB
AT1 AT2
CCB
Ca++
 ↓ BP  ↓ BP
↓ Vasoconstriction
↑ Vasodilation
↑ Arterial vasodilation
↓ Aldosterone secretion
↓ Catecholamine release
Figure 3 Complementary mechanisms by which ARBs and CCBs lower BP. ARBs block the effects of angiotensin II at the AT1 receptor thus suppressing vasoconstriction. 
CCBs block the entry of calcium into cells allowing arterial smooth muscle to relax causing peripheral vasodilation. These complementary activities cause reductions in blood 
pressure. Reproduced with permission from Neutel JM. Complementary mechanisms of angiotensin receptor   blockers and calcium channel blockers in managing hypertension. 
Postgrad Med. 2009;121(2):40–48. Copyright © 2009 JTe Multimedia, LLC.
Abbreviations: ARB, angiotension receptor blocker; CCB, calcium channel blocker; MOA, mechanism of action.
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therapy than with equivalent dosages of the individual 
  monotherapies (Figure 4) and were significant for all active 
treatment groups (P , 0.001) and placebo (P = 0.024).
An antihypertensive effect was evident within the first 
2 weeks of active treatment, during which time the greatest 
mean SeBP reduction occurred. Reductions in BP plateaued 
at Week 4 and were maintained until study end without further 
notable reductions.
The prespecified BP goal of ,140/90  mmHg 
(,130/80 mmHg for patients with diabetes) was attained 
by a significantly greater proportion of combination therapy 
recipients than by monotherapy recipients. After 8 weeks of 
treatment, the proportion of amlodipine + olmesartan medox-
omil recipients achieving their BP goal ranged from 35.0% 
to 53.2%, compared with 20.0%, 26.4%, and 36.3% receiv-
ing olmesartan medoxomil 10, 20, or 40 mg/day, and 21.1% 
and 32.5% receiving amlodipine 5 or 10 mg/day (P , 0.005 
combination vs monotherapies) (Figure 5).
Prespecified subanalyses  
of the COACH patient cohort
Prespecified subgroup analyses showed that the amlodipine 
+ olmesartan medoxomil combination produced significant 
reductions from baseline in mean SeDBP and SeSBP, 
  irrespective of the severity of hypertension (Stage 1 or 2) or 
prior antihypertensive treatment.37
Most amlodipine + olmesartan medoxomil   combinations 
were associated with significantly greater SeBP   reductions 
than component monotherapies in patients with Stage 
1   hypertension and all in Stage 2 patients.37 Furthermore, 
of patients with Stage 1 hypertension, 65.6% to 80.0% who 
received amlodipine + olmesartan medoxomil combination 
therapy achieved the prespecified BP goal, compared with 
40.5% to 66.7% of monotherapy component recipients 
(P , 0.0001 across treatment groups) (Figure 6). Among 
those with Stage 2 hypertension, combination therapy that 
included amlodipine 10 mg resulted in 40.5% to 49.2% of 
patients achieving BP goal, compared with 13.1% to 29.2% of 
monotherapy component recipients (Figure 6).37 In a post hoc 
analysis of patients with baseline SeSBP $ 180 mmHg, 
combination amlodipine + olmesartan medoxomil therapy 
produced even greater SeSBP reductions from baseline of 
43.5 and 40.8 mmHg for the 10 + 20 and 10 + 40 mg   dosages, 
respectively.37
Among antihypertensive treatment-naive and   non-naive 
patients, all combination therapy dosages resulted in 
  significantly greater SeBP reductions compared with 
  monotherapy.37 Proportionally, more patients (both treat-
ment naive [36.2%–55.0%] and non-naive [31.3%–52.9%]) 
who received combination therapy achieved prespeci-
fied BP goals than their counterparts who received 
  monotherapies (21.8%–37.7% and 18.0%–35.5%, respec-
tively; P , 0.0001 across all treatment groups for combination 
vs monotherapy).37
Prespecified subgroup analyses of the COACH study 
based on age ($65 or ,65 years), race (Black or non-Black),     
or absence of diabetes, and BMI ($30 or ,30 kg/m2) showed 
that combination therapy enabled greater SeBP reduc-
tions than monotherapy.38 Changes from baseline in mean 
SeBP for amlodipine + olmesartan   medoxomil 10 + 40 mg 
were −33.9/−20.9 mmHg in patients aged $65 years, 
−28.7/−15.7 mmHg for Blacks, −30.3/−18.4 mmHg in 
patients with diabetes, and −29.7/−17.9 mmHg in patients 
with a BMI $ 30 kg/m2. Combination therapy generally 
allowed more patients to achieve BP goal than monotherapy. 
The rate of BP goal achievement was lower in patients with 
diabetes due to the aggressive target of ,130/80 mmHg.38
Amlodipine/olmesartan medoxomil 
following amlodipine or olmesartan 
medoxomil monotherapy
The efficacy of amlodipine/olmesartan medoxomil   combination 
therapy has also been assessed in clinical studies where 
patients initially received amlodipine39 or   olmesartan medox-
omil40 monotherapy (Table 1). The efficacy of amlodipine/
olmesartan medoxomil following amlodipine monotherapy 
was assessed in a randomized, double-blind, parallel-group, 
multicenter study.39 The study comprised of 24 weeks of 
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with permission from Table III in Chrysant et al).36 
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active treatment. In Period I (Weeks 0 to 8) patients received 
open-label amlodipine 5 mg. At the end of the open-label 
period, non-responders, with mean SeDBP $ 90 mmHg, mean 
SeSBP $ 140 mmHg, and mean 24-hour DBP $ 80 mmHg 
(with $30% daytime DBP . 85 mmHg), entered Period II, 
where patients were randomized to 1 of 4 double-blind treat-
ment groups: amlodipine 5 mg plus placebo or a combination 
of   amlodipine/olmesartan medoxomil 5/10, 5/20, or 5/40 mg 
for 8 weeks. At the end of Period II, patients with SeDBP 
, 90 mmHg or SeSBP , 140 mmHg remained on their cur-
rent therapy for a further 8 weeks (Period III). For patients 
with SeDBP $ 90 mmHg and SeSBP $ 140 mmHg, study 
medication was further up-titrated (Table 1).
The primary efficacy endpoint was change in mean SeDBP 
from the end of Period I (after the amlodipine run-in) to the 
end of Period II and the secondary endpoint was change in 
mean SeSBP values for the same period. All SeBP changes 
for combination therapy were significant compared with 
amlodipine monotherapy (P , 0.05 vs amlodipine/olm-
esartan medoxomil 5/10 mg; P , 0.0001 vs amlodipine/
olmesartan medoxomil 5/20 and 5/40 mg).39
Up-titration of medication for patients not at the SeBP 
goal at the end of Period II for a further 8 weeks of therapy 
enabled additional SeBP reductions and allowed more 
patients to achieve their BP goal (Table 1). Overall, at the 
end of the 24-week duration of the study, 63% of patients 
achieved a SeBP threshold of ,140/90 mmHg.39
In a similar study, the efficacy of amlodipine/olm-
esartan medoxomil following olmesartan medoxomil 
monotherapy was examined.40 The primary efficacy end-
point was the change in mean SeDBP from the end of the 
olmesartan medoxomil monotherapy period to the end 
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of the 8-week randomized phase. All treatments signifi-
cantly reduced SeDBP from baseline in a dose-dependent 
manner (Table 1). The achievement of BP goal (SeBP , 
140/90 mmHg; ,130/80 mmHg for patients with diabetes) 
was also assessed. Treatment with amlodipine/olmesartan 
medoxomil 5/20 or 10/20 mg combination therapy led to 
significantly greater proportions of patients achieving their 
BP goal, compared with olmesartan medoxomil mono-
therapy; P , 0.01 for both combinations vs monotherapy 
(Table 1).40 It is worth noting that the highest United 
States FDA-approved dosage of olmesartan medoxomil 
monotherapy (40 mg/day) was not used in this European 
study.24
Long-term efficacy of amlodipine/
olmesartan medoxomil
The long-term efficacy of the amlodipine + olmesartan 
medoxomil combination was investigated in a 44-week 
open-label extension (OLE) of the eight-week COACH 
study.41 At the start of the OLE, 1,684 patients were 
switched to amlodpine/olmesartan medoxomil 5/40 mg. 
Patients who were not at the SeBP goal (,140/90 mmHg; 
,130/80 for patients with diabetes) were up-titrated as 
necessary to amlodipine/olmesartan medoxomil 10/40 
mg, followed by the addition of HCTZ 12.5 and 25 mg. 
Back titration and dose adjustment were permitted. 
Approximately one-quarter of patients (n = 419) were 
up-titrated to amlodipine/olmesartan medoxomil 10/40 
mg + HCTZ 25 mg. Mean SeBP changes from baseline 
(measured at randomization into the 8-week study) 
ranged from −30.0/−19.3 mmHg for amlodipine/olm-
esartan medoxomil 5/40 mg to −36.1/−19.8 mmHg for 
amlodipine/olmesartan medoxomil 10/40 mg + HCTZ 
25 mg. Overall, 66.7% of patients in the OLE achieved 
the SeBP goal.41
An extension of the Volpe et al39 study was also 
  conducted. Out of the patients who completed Period 
III, 692 were enrolled into a 28-week OLE conducted 
to assess the effectiveness of long-term treatment with 
amlodipine/olmesartan medoxomil with or without the 
addition of HCTZ.42 Patients initially received amlo-
dipine/olmesartan medoxomil 5/40 mg (one patient 
received 10/40 mg), and most patients (63%) remained on 
this dosage. If SeDBP was .90 mmHg and SeSBP was 
.140 mmHg, patients were up-titrated to amlodipine/
olmesartan medoxomil 10/40 mg followed by the addition 
of HCTZ 12.5 and 25 mg as needed. Of the patients who 
completed the OLE phase, 436 remained on amlodipine/
Table 1 Randomized double-blind, parallel-group, multicenter studies assessing efficacy of AML/OM following AML or OM monotherapy
Study Volpe et al 200939 Barrios et al 200940
N 1,017 722
BP inclusion criteria SeDBP $ 100 mmHg, SeSBP $ 160 mmHg, and mean 24-hr DBP $ 84 mmHg with $30% of daytime DBP . 90 mmHg 
Patient characteristics
Mean age, years 55.8 56.8
Aged $ 65 years (%) 21.5 27.0
Caucasian (%) 99.7 100
Males (%) 61.1 48.9
Diabetes mellitus (%) 7.2 8.0
Mean baseline SeBP 164/102 mmHg 171/104 mmHg
Open-label monotherapy AML 5 mg (8 wks) OM 20 mg (8 wks)
Efficacy of treatment from the end of monotherapy period to end of first 8-week randomized, double-blind phase
Change in mean BP and 
attainment of SeBP goal 
,140/90 mmHg 
(,130/80 mmHg  
for diabetes)
Treatment (mg/day) Change (mmHg) Goal (%) Treatment (mg/day) Change (mmHg) Goal 
(%)
AML 5 −9.7/−5.7 30 OM 20 −10.8/−7.6 28.5
AML/OM 5/10 −13.2/−7.7 39 AML/OM 5/20 −16.1/−10.4 45.8
AML/OM 5/20 −15.4/−9.5 54 AML/OM 10/20 −16.7/−10.9 44.5
AML/OM 5/40 –16.8/−9.6 51
Efficacy of treatment at end of second 8-week double-blind phase after dose titration
Change in mean BP and 
attainment of SeBP goal 
,140/90 mmHg 
(,130/80 mmHg for 
diabetes)
Treatment (mg/day) Change (mmHg) Goal (%) N/A
AML/OM 5/0→5/20 −12.6/−8.2 38
AML/OM 5/10→5/20 −7.5/−5.6 28
AML/OM 5/20→5/40 −10.6/−6.2 36
AML/OM 5/40→10/40 −12.3/−8.2 47
Abbreviations: AML, amlodipine; BP, blood pressure; DBP, diastolic BP, OM, olmesartan medoxomil; SeBP, seated BP; SeDBP, seated DBP; SeSBP, seated SBP.Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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olmesartan medoxomil 5/40 mg, 142 were up-titrated to 
amlodipine/olmesartan medoxomil 10/40 mg, and 68 and 
27 required the addition of HCTZ 12.5 mg and 25 mg, 
respectively.   Up-titration from amlodipine/olmesartan 
medoxomil 5/40 mg enabled additional SeBP changes 
of −8.8/−5.5, −10.2/−6.3, and −3.8/−3.7 mmHg with 
each titration step. The overall rate of goal achievement 
(,140/90 mmHg; ,130/80 mmHg for patients with 
diabetes) was 66.9%.42
A post hoc analysis of this OLE determined the 
  magnitude of BP reductions observed in patients who 
received the amlodipine/olmesartan medoxomil 5–10/40 mg 
  combination.43 The proportions of patients with categori-
cal SeSBP   reductions from baseline of #15 mmHg, .15 
to #30 mmHg, .30 to #45 mmHg, and .45 mmHg 
were 12.8%, 36.0%, 35.3%, and 15.9%, respectively. 
  Unsurprisingly, the   greatest SeSBP reductions were asso-
ciated with the highest rates of achievement of a target of 
,140 mmHg, with 97.8%, 89.7%, 77.4%, and 55.4% from 
the .45 mmHg, .30 to #45 mmHg, .15 to # 30 mmHg, 
and #15 mmHg groups, respectively.43
Efficacy of amlodipine  
and olmesartan medoxomil over 
the 24-hour dosing interval
Cardiovascular events appear to occur more frequently in the 
morning, a phenomenon that has been linked with activation 
of the sympathetic nervous system that results in hormonal 
and physiological changes, including an increase in heart 
rate and BP elevation.44 These morning BP elevations dif-
fer from BP alterations observed with normal changes in 
position.
Ambulatory BP monitoring (ABPM) is an effective 
and accurate method of hypertension diagnosis and a 
valuable tool for optimizing hypertension management.45 
Ambulatory devices are particularly useful for the detec-
tion of   white-coat hypertension or masked hypertension 
and for   monitoring patients who are receiving complex 
antihypertensive   treatment protocols.46 The use of ABPM 
also allows the efficacy of antihypertensive medications 
to be monitored over a 24-hour dosing interval. However, 
there is a lack of current consensus guidance for ambula-
tory BP treatment goals.
Two recent studies have indicated that amlodipine/olm-
esartan medoxomil provides effective BP lowering over a 
24-hour period in patients not adequately controlled with 
amlodipine 5 mg/day monotherapy.47,48
24-Hour BP control in patients 
treated with an amlodipine/
olmesartan medoxomil titration 
regimen
At the American Society of Hypertension (ASH) 2009 Annual 
Scientific Meeting, data were presented describing the efficacy 
of an amlodipine/olmesartan medoxomil-based titration 
regimen.47 Seated BP inclusion criteria were SeSBP $ 140 and 
#199 mmHg and SeDBP $ 90 and #109 mmHg.49 Patients 
with hypertension received   monotherapy with amlodipine 
5 mg/day and were up-titrated at 3-week intervals to combina-
tion amlodipine/  olmesartan medoxomil dosages of 5/20, 5/40, 
and 10/40 mg if SeBP was $120/80 mmHg. Of the 185 patients 
who entered the study, 56.8% were male and the mean age was 
56.8 years. Baseline ambulatory BP was 144.8/85.7 mmHg for 
those patients with baseline and end-of-study ABPM readings 
(n = 172).47 Baseline SeBP for the efficacy cohort (n = 185) 
was 158.0/92.8 mmHg.50 The primary efficacy endpoint was 
the change from baseline in mean 24-hour SBP as assessed by 
ABPM at Week 12. At Week 12, the titration regimen enabled 
a change from baseline in mean 24-hour ambulatory BP of 
−21.4/−12.7 mmHg, and ambulatory BP was reduced from 
baseline throughout the dosing interval including the last 6, 4, 
and 2 hours.47,51 A cumulative SeBP target of ,140/90 mmHg 
was achieved by 76.8% of patients.50
24-Hour BP control in patients 
receiving amlodipine/olmesartan 
medoxomil who previously were 
non-responders to amlodipine 
monotherapy
Data recently presented at the ESH 2009 Annual Scientific 
Meeting showed that reductions in mean 24-hour, daytime, 
and nighttime ambulatory BP were significantly greater with 
amlodipine/olmesartan medoxomil combination therapy than 
with amlodipine monotherapy in patients who had not responded 
adequately to amlodipine (P , 0.0001 for each combination 
dosage vs amlodipine monotherapy).48   Furthermore, patients 
who did not achieve BP goals had further reductions in BP 
following 8 weeks of dose   up-titration.48 Changes in mean 
24-hour ambulatory BP   values from baseline at the end of 
the double-blind period   associated with amlodipine mono-
therapy were −3.4/−2.8 mmHg, compared with changes of up 
to −10.1/−7.2 mmHg (for the maximum combination therapy 
dosage of 5/40 mg). Dose   up-titration for a further 8 weeks 
occurred at the end of the double-blind period in patients who Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
101
Amlodipine/olmesartan medoxomil combination therapy
were still inadequately controlled (DBP $ 90 mmHg and SBP 
$ 140 mmHg) and provided additional clinically relevant 
ambulatory BP reductions, eg, further mean 24-hour ambula-
tory BP changes from baseline of −8.8/−6.6 mmHg for patients 
up-titrated from amlodipine/olmesartan medoxomil 5/40 to 
10/40 mg.48 These data represent a subanalysis of data from the 
study conducted by Volpe et al.39
Safety and tolerability  
of amlodipine/olmesartan 
medoxomil
In large controlled studies, the amlodipine/olmesartan 
medoxomil combination of 5–10/10–40 mg was generally 
well tolerated.36,39,40 In all studies, the incidences of adverse 
events were comparable among the different amlodipine/
olmesartan medoxomil dose combinations, the olmesartan 
medoxomil or amlodipine monotherapy groups, and 
placebo.36,39,40 Overall, most adverse events were of a mild 
nature and were consistent with the tolerability profile of 
either CCB or ARB therapy. Across three clinical trials36,39,40 
in which patients received combination amlodipine/olm-
esartan medoxomil dosages of 5–10/10–40 mg, commonly 
  occurring drug-related adverse events were headache 
(0.0%–6.9%) and dizziness (0.0%–5.0%); two trials indi-
cated rates of peripheral edema of 0.5% to 2.3%,39,40 whereas 
in the third trial (COACH),36 reported rates for edema were 
between 18.0% and 26.5%, which is probably due to the 
fact that this aspect of drug safety was actively assessed in 
this study.
In 2 trials that compared combination amlodipine/ 
olmesartan medoxomil therapy with amlodipine 
  monotherapy, the incidence of peripheral edema was lower 
for combination therapy compared with amlodipine mono-
therapy when the DHP-CCB dosage was 539 or 10 mg.36 In the 
COACH trial, among patients receiving amlodipine 10 mg, 
the frequency of edema was 36.8%, but this was reduced 
to 25.6% and 23.5% in patients who received olmesartan 
medoxomil 20 mg or 40 mg, respectively, in combination 
with amlodipine (P , 0.05 for both combination dosages 
vs amlodipine monotherapy).36 Similarly, in the Volpe et al 
study, the lower dosage of amlodipine monotherapy (5 mg/
day) was   associated with rates of peripheral edema that were 
2- to 4-fold higher than in those who received amlodipine/
olmesartan medoxomil 5/10–40 mg combinations (2.1% vs 
0.5%–1.1%; descriptive data only).39
In the ABPM study presented at ASH 2009, the most 
common drug-related adverse events reported in patients 
were peripheral edema (4/185) and dizziness (2/185), and 
there were no reports of headache, orthostatic hypotension, 
or hypotension.47
In the OLE of the COACH study, no major safety issues 
emerged as a consequence of extended therapy.41 The incidence 
of edema continued to be monitored in the OLE and increases 
in severity were reported as adverse events. Incidences of 
edema determined to be related to the study drug ranged from 
7.0% to 11.1% in patients who received amlodipine/olmesartan 
medoxomil 5/40 and 10/40 mg, respectively.41
In the 28-week extension of the Volpe et al study,39 
drug-related incidences of edema were low in patients who 
received amlodipine/olmesartan medoxomil 5/40 mg (0.7%) 
and 10/40 mg (1.6%). No edema was reported in patients who 
were administered HCTZ as a component of the combination 
regimen.42
Patient perspectives
Fixed-dose combination therapy provides a number of 
  potential advantages, including better adherence, simplified 
dosing regimens and titration, reduced likelihood of adverse 
events, lower cost, and improved quality of life.5,15
The simplified dosing schedule associated with   combination 
therapy is linked to improved adherence.   Multiple   medications 
and complex treatment regimens lead to poor patient 
  adherence.5 In particular, adherence to   antihypertensive treat-
ment decreases as dosing frequency increases.52 In a Canadian 
study (N = 198), significantly more patients with hypertension 
randomized to a   once-daily   amlodipine   regimen took their 
medication regularly,   compared with patients receiving a twice-
daily diltiazem regimen.53 In another study of patients with 
diabetes, the average percentage of doses taken decreased by 
more than 50% when dosing frequency of an oral antidiabetic 
agent was increased to 3 times daily from a once-daily   regimen 
(79% vs 38%).54 These results are supported by findings from 
2 more recent studies in patients with hypertension, where 
observed adherence was greater with fixed-dose combinations 
than with free   combination therapy.55,56 It is worth noting that 
in the earlier study in patients with diabetes, the investigators 
found that, for the most part, the major nonadherence event 
was dose   omission.54 However, more than 33% of patients took 
more doses than were prescribed, indicating that decreasing the 
dose frequency may increase the risk of overmedication.54
Because antihypertensive combinations like amlodipine/
olmesartan medoxomil are more effective than single-drug 
treatment, BP control can be achieved potentially more 
  quickly.57 Titration of dose is simplified with fixed-dose combi-
nation therapy, which increases convenience for the patient,5,15 
and may therefore increase compliance and adherence.12Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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Patients are less likely to experience adverse effects with 
combination therapy because lower doses of the individual 
agents can be used.16 In addition, one agent can attenuate adverse 
effects caused by the other agent;5,15 for example, as discussed 
in the tolerability section of this paper,   olmesartan medoxomil 
ameliorates the dose-related peripheral edema that is associated 
with amlodipine. A further illustration of the adverse effect neu-
tralizing properties of one agent over another is the attenuation 
of thiazide-induced hypokalemia with concomitant use of ARBs, 
ACE inhibitors, or   potassium-sparing diuretics.5
Fixed-dose combination therapy may incur lower 
overall costs than treatment with the component agents 
separately because of lower prescription costs and fewer 
regimen   modifications, leading to fewer physician visits.57,58 
  Modifications (not including discontinuations) to drug 
therapy, regardless of the antihypertensive drug class, have 
been associated with significantly higher health service costs 
in the first 12 months of therapy.57
In 2 retrospective studies, the annual cost of   treatment 
was significantly lower for patients with hypertension 
  receiving fixed-dose benazepril/amlodipine than for 
those receiving the free combination.55,56 Results from a 
  retrospective database analysis showed that recipients of 
a once-daily, single-capsule, fixed-dose combination of 
amlodipine/benazepril required fewer medical resources 
and that annual per-patient CV-related medical costs were 
less than those associated with a similar regimen comprised 
of separate components.55 Similarly, in a longitudinal 
cohort analysis of South Carolina Medicaid claims, fixed-
combination antihypertensive therapy was associated with 
a significant reduction in average total costs of 12.5%, 
compared with free-  combination therapy (P , 0.003).56 
Furthermore, according to a simulation model, CCB/ARB 
combination therapy may be more cost effective than 
monotherapy with either agent alone for lifetime treatment 
of hypertension in Japan.59
Combination antihypertensive therapy may also improve 
health related quality of life outcomes over monotherapy. 
A study in patients with poorly controlled hypertension 
on   low-dose amlodipine showed that the combination 
of   amlodipine and the β-blocker betaxolol significantly 
improved health-related quality of life, whereas increasing 
the dose of amlodipine had no significant effect.60
Conclusion
The prevalence of hypertension is increasing worldwide and 
is a powerful, independent risk factor for CV and renal dis-
ease, placing considerable burden on health care resources. 
In addition, the majority of patients with hypertension have 
inadequately controlled BP. It is now recognized that most 
patients with hypertension will require combination therapy 
with two or more antihypertensive drugs to achieve BP goals. 
Extensive evidence shows that a combination of antihyperten-
sive agents with complementary mechanisms of action have 
a number of additive benefits over monotherapy including a 
greater BP response and percentage of responders, a reduction 
in side effects, simplification of dose titration, and improved 
adherence rates.
The combination of a DHP-CCB (amlodipine) with 
an ARB (olmesartan medoxomil) is effective in patients 
with mild-to-severe hypertension, and significantly greater 
  proportions of patients achieve BP goals with this   combination 
treatment compared with the component monotherapies. The 
efficacies of amlodipine/olmesartan medoxomil   combination 
therapy regimens are maintained over a 24-hour dosing inter-
val. Furthermore, in large   clinical trials, amlodipine/olmesar-
tan medoxomil combinations exhibit favorable   tolerability 
profiles. Of note, the incidence of peripheral edema, an 
adverse event commonly   associated with DHP-CCB mono-
therapy, was significantly less f  requent in   amlodipine/olm-
esartan medoxomil combinations   compared with high-dose 
amlodipine monotherapy, where this event was specifically 
evaluated in a clinical trial.
The combination of amlodipine/olmesartan   medoxomil 
is effective for achieving BP goals in a wide range of 
patients with hypertension, including patients who have not 
responded to monotherapy with either agent. The clinical evi-
dence   discussed in this review provides a strong   rationale for 
the use of this combination as an antihypertensive treatment 
strategy, particularly in a single-pill formulation, regardless 
of patient age, gender, or ethnicity or those with common 
comorbid conditions such as diabetes.
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